Global Agriculture

Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit

Quick Share

24 January 2024, Israel: Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN.TASE: EVGN), announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024.

The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up. Dr. Haber will join two industry panel discussions: “The Future of Microbiome Therapeutics as Co-therapies: Investment & Development Considerations” on January 30, 2024, at 3:30pm GMT, and “Microbiome Business Pioneers: An Evaluation of Microbiome Industry Verticals & Future Perspectives” on February 1, 2024, at 4:15pm GMT.

Dr. Haber will be available for one-on-one meetings at the conference, and interested parties can contact the investor or public relations team.

Also Read: DLF to close the R&D site in Landskrona, Sweden

(For Latest Agriculture News & Updates, follow Krishak Jagat on Google News)

Quick Share